The price of Bausch Health Companies Inc (NYSE:BHC) shares last traded on Wall Street rose 0.10% to $10.05.
BHC stock price is now 11.88% away from the 50-day moving average and 22.50% away from the 200-day moving average. The market capitalization of the company currently stands at $3.67B.
With the price target enhanced from $9 to $16, Jefferies Upgraded its rating from Hold to Buy for Bausch Health Companies Inc (NYSE: BHC). , while ‘Truist’ rates the stock as ‘Hold’
In other news, Carson Seana, EVP, General Counsel sold 6,313 shares of the company’s stock on Mar 04 ’24. The stock was sold for $61,867 at an average price of $9.80. Upon completion of the transaction, the EVP, General Counsel now directly owns 499,905 shares in the company, valued at $5.02 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 05 ’23, EVP, General Counsel Carson Seana sold 220 shares of the business’s stock. A total of $1,624 was realized by selling the stock at an average price of $7.38. This leaves the insider owning 382,925 shares of the company worth $3.85 million. A total of 2.41% of the company’s stock is owned by insiders.
During the past 12 months, Bausch Health Companies Inc has had a low of $5.57 and a high of $11.46. The fifty day moving average price for BHC is $8.98 and a two-hundred day moving average price translates $8.20 for the stock.
The latest earnings results from Bausch Health Companies Inc (NYSE: BHC) was released for Dec, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $1.15, beating analysts’ expectations of $1.02 by 0.13. This compares to -$1.13 EPS in the same period last year. The company reported revenue of $2.41 billion for the quarter, compared to $2.19 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.8 percent. For the current quarter, analysts expect BHC to generate $2.15B in revenue.
